Is This Drug a Statin Alternative?
METHODOLOGY:
Previous studies have shown the efficacy of inclisiran in lowering the level of LDL cholesterol when used in combination with statins in patients with a high risk for atherosclerosis; however, its efficacy as a monotherapy without statins remains uncertain.
Researchers conducted a 6-month multinational, randomized, phase 3 study to compare the efficacy and safety of inclisiran with those of placebo or ezetimibe in reducing levels of LDL cholesterol.
They included 350 participants (mean age, 46.1 years; 62.6% women) with no history of atherosclerotic cardiovascular disease , diabetes, or familial hypercholesterolemia and a fasting LDL cholesterol level of 100-190 mg/dL.
Participants were randomly assigned to receive subcutaneous inclisiran (n = 174), oral ezetimibe (n = 89), or matching placebo (n = 87), with inclisiran administered on days 1 and 90.
The primary endpoint was the percentage change in the level of LDL cholesterol from baseline to day 150; several secondary endpoints, including the absolute change in LDL and safety, were assessed.
TAKEAWAY:
By day 150, participants who received inclisiran showed a 47.9% greater reduction in the level of LDL cholesterol than those who received placebo and a 35.4% greater reduction than those who received ezetimibe ( P < .0001 for both).
< .0001 for both). The absolute reduction in the level of LDL cholesterol and the percentage reduction in PCSK9 levels were also greater in participants who received inclisiran than in those who received placebo or ezetimibe ( P < .0001 for all).
< .0001 for all). In the group who received inclisiran, levels of lipoprotein(a) decreased by 25.2% compared with placebo ( P = .001) and by 24.3% compared with ezetimibe ( P = .0002) by day 150.
= .001) and by 24.3% compared with ezetimibe ( = .0002) by day 150. Similar rates of treatment-emergent adverse events were noted across the three groups, with no new safety concerns.
IN PRACTICE:
'There is a significant unmet clinical need for therapies that address both statin intolerance and adherence in primary prevention,' the researchers noted. 'Inclisiran is potentially uniquely positioned to meet these challenges owing to its first-in-class mechanism of action, favorable safety profile, and infrequent twice-yearly dosing,' they added.
SOURCE:
This study was led by Pam R. Taub, MD, of the University of California in San Diego. It was published online on June 9, 2025, in Journal of the American College of Cardiology .
LIMITATIONS:
A short follow-up duration and limited sample size prevented the researchers from evaluating the cardiovascular outcomes of lowering the level of LDL cholesterol with inclisiran. The analysis lacked direct comparison with statins, anti-PCSK9 monoclonal antibodies, or bempedoic acid. The response of LDL with ezetimibe was lower than that observed in other studies.
DISCLOSURES:
This study received funding from Novartis Pharma. Two authors reported receiving compensation for serving as principal investigators of this trial, and another author reported serving as a consultant for multiple pharmaceutical companies including the funding agency. Several other authors reported serving as employees of the US or Switzerland wings of the funding agency or being principal investigator, consultants, and/or holding shares in the same.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Washington Post
an hour ago
- Washington Post
Citizen scientists pinpoint 10,000 eclipsing star pairs
Citizen scientists have successfully located thousands of previously unknown pairs of 'eclipsing binary' stars, NASA announced in June. The ongoing initiative helps space researchers hunt for 'eclipsing binary' stars, a rare phenomenon in which two stars orbit one another, periodically blocking each other's light. These star pairs offer important data to astrophysicists, who consider the many measurable properties of eclipsing binaries — and the information they bear about the history of star formation and destruction — as a foundation of the field.
Yahoo
2 hours ago
- Yahoo
Hot electrons from quantum dots break tough bonds using 99% less energy: Study
Imagine using just a flicker of sunlight to break stubborn chemical bonds that once required intense energy or toxic chemicals to split. This may sound almost impossible, but chemists at the Hong Kong University of Science and Technology (HKUST) have found an interesting way to achieve it. By supercharging quantum dots, tiny particles thousands of times smaller than a grain of sand, they've developed a highly efficient, light-powered tool called a super photoreductant. This tool can revolutionize the field of organic synthesis, according to the researchers. Until now, quantum dots have shown promise as photocatalysts but have fallen short in practice. Their full potential was locked behind complex physics, and scientists struggled to unlock efficient hot electrons needed to drive challenging chemical reactions, but with the super photoreductant, this would change. Quantum dots (QDs) are nano-sized semiconductors that can absorb light and release energy in powerful ways. Researchers have long known that QDs could work as photocatalysts, substances that use light to speed up chemical reactions. However, despite years of research, they didn't outperform traditional small-molecule photosensitizers because scientists didn't fully understand how to control or boost their most valuable feature: the hot electrons, fast-moving electrons that can help tear apart strong chemical bonds in a target molecule. While scientists have explored ways to generate these electrons from QDs, doing so efficiently and under calm and non-damaging conditions, remained a major challenge. To overcome this, the HKUST team developed a new photocatalytic system using manganese-doped CdS/ZnS quantum dots. The researchers deployed a special quantum effect called the two-photon spin-exchange Auger process to produce hot electrons far more efficiently than before. This process allows two low-energy photons (particles of light) to combine their energy inside the QD to generate one ultra-energetic hot electron. Essentially, the team created a way for quantum dots to act like tiny energy multipliers, absorbing gentle visible light and converting it into a strong punch that can break bonds. The results were impressive. The system developed could drive tough reactions like the Birch reduction, a reaction normally requiring liquid ammonia and alkali metals. It could also break a wide variety of chemical bonds, C–Cl, C–Br, C–I, C–O, C–C, and even N–S bonds. Even more impressively, it could handle molecules with extremely negative reduction potentials down to −3.4 volts vs. SCE (Standard Calomel Electrode), which are usually considered too stubborn for light-driven systems. All of this was done using just one percent of the light energy needed by conventional systems. That's a big leap in efficiency. Moreover, the system allows researchers to turn the reaction on or off just by adjusting the light's intensity. This feature could be used to program complex sequences of reactions in the future, like a chemical computer. The discovery could have huge implications for how we manufacture everything from pharmaceuticals to plastics. For example, industries that rely on chemical synthesis could use the light-powered approach to reduce their dependence on harsh chemicals, lower energy use, and create less waste. The research also shows how quantum-confined materials, like these custom-built QDs, can unlock new types of chemistry that were previously thought impossible. "The study underscores the unprecedented potential of quantum-confined semiconductors to facilitate challenging organic transformations that were previously unattainable with conventional molecular photocatalysts," the scientists note. However, some challenges remain. For instance, these systems still need to be tested on a broader range of reactions and in industrial-scale conditions. The long-term stability and cost of producing such specialized quantum dots is also something that will decide the success of this approach. The researchers are now exploring ways to refine this light-based system to drive even more complex chemical transformations. The study has been published in the journal Nature Communications.
Yahoo
3 hours ago
- Yahoo
Breakthrough gene therapy jab reverses hearing loss in weeks
A single jab of a breakthrough gene therapy could reverse hearing loss in people within weeks, according to new research. The cutting-edge therapy improved hearing in children and adults with congenital deafness or severe hearing impairment, with a 7-year-old regaining almost full hearing in a clinical trial, researchers from Sweden's Karolinska Institutet said. The clinical trial, detailed in the journal Nature Medicine, showed that a healthy copy of the OTOF gene injected in the inner ear improved hearing of all 10 participants. The small-scale trial included people who had a genetic form of deafness or severe hearing impairment caused by mutations in a gene called OTOF. These mutations cause a deficiency of the protein otoferlin, which plays a key role in transmitting sound signals from the ear to the brain. While the therapy seemed to work best in children, researchers said, it could benefit adults as well. In the trial, a synthetic, harmless version of the adeno-associated virus was used to deliver a properly functional OTOF gene to the inner ear via a single injection. The effects of the therapy were evident in the majority of patients, whose hearing recovered rapidly after just a month. After six months, researchers noted considerable hearing improvement in all participants, with their average volume of perceptible sound improving from 106 decibels to 52. Those between the ages of five and eight responded best to the treatment, the study found. One seven-year-old girl quickly recovered almost all her hearing, and she was able to hold daily conversations with her mother four months afterwards. 'This is the first time that the method has been tested in teenagers and adults,' Maoli Duan, an author of the study from Karolinska Institutet, said. "Hearing was greatly improved in many of the participants, which can have a profound effect on their life quality. We will now be following these patients to see how lasting the effect is.' Researchers also found that the treatment was safe and well-tolerated. Participants did not report any serious adverse reactions in the follow-up period of 6-12 months. The most common reaction was a reduction in the number of the immune system's neutrophils, a type of white blood cell. "OTOF is just the beginning," Dr Duan said, adding that researchers were working on other common genes behind deafness such as GJB2 and TMC1. 'These are more complicated to treat, but animal studies have so far returned promising results. We are confident that patients with different kinds of genetic deafness will one day be able to receive treatment.'
